Previous Article | Next Article ![]()
Journal of Virology, January 2002, p. 673-687, Vol. 76, No. 2
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.76.2.673-687.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.
MRC Virology Unit, Institute of Virology, Glasgow G11 5JR, United Kingdom
Received 9 July 2001/ Accepted 1 October 2001
|
|
|---|
|
|
|---|
1,250 Å in diameter and
160 Å thick within the virus particle. The assembly pathway of the mature capsid has striking parallels with those of double-stranded DNA bacteriophages, such as T4 and P22 (2, 27). One common feature is that these viruses all have internal scaffolding proteins that are not present in the mature virion but are required for the formation of the precursor capsid prior to encapsidation of the genome. Two genes specify the scaffolding proteins of HSV-1. UL26.5 encodes the major component of the scaffold or protein core present in the cavity of the procapsid, the precursor capsid into which the DNA is packaged. UL26 specifies the minor constituent of the scaffold. The precursor protein of UL26 consists of two distinct functional domains. The N-terminal region, comprising 247 amino acids, is a serine protease, and the C-terminal region, of which the last 329 amino acids are identical to the full-length UL26.5 product, interacts with the major scaffolding protein (7, 15, 16, 34). In the absence of the scaffolding proteins, incomplete capsids are produced (5, 33, 35). The activity of the protease is not required for the assembly of the capsid shell, and large numbers of intact capsids are generated in the presence of the UL26.5 product only or the scaffolding portion of the UL26 protease (8, 25, 33, 35). Although the UL26 product can partially replace the UL26.5 protein, its prime function is likely to be the release of the scaffold from the capsid through the action of the maturational protease (17, 30). During capsid assembly, the UL26 and UL26.5 products associate and interact with the major capsid protein VP5, which forms the 12 pentamers at the vertices of the capsid and the 150 hexamers on the triangular faces (4, 11, 13, 20, 34, 37). The capsid shell proteins VP19C and VP23 bind together to form a trimer, referred to as the triplex, consisting of two copies of VP23 and one copy of VP19C, which connects adjacent capsomers on the capsid (20, 31, 32). The maturational protease is required for the conformational transition of procapsids to mature angularized capsids in vivo (8, 21, 25, 29). The protease cleaves itself at an internal site, separating the proteolytic domain, VP24, from the scaffolding region, VP21 (6, 14). It also breaks the connections between the scaffold and the inner capsid shell wall by cleaving the carboxy-terminal ends of scaffolding proteins, detaching the region containing the VP5 binding site from the scaffolding core (38). This proteolytic step is essential for the release of the scaffold from the capsid and packaging of viral DNA (8, 25). In the absence of capsid shell proteins, the HSV-1 major scaffolding protein readily forms spherical particles approximately 60 nm in diameter when extracted from purified capsids and renatured (18). In insect cells infected with a recombinant baculovirus expressing the major scaffolding protein, scaffold-like particles are also detected, especially when the C-terminal cleaved form (VP22a) is synthesized or produced by proteolytic cleavage. In addition, large aggregates of protein with a less defined structure are observed (24). Recently, a purified hybrid human cytomegalovirus (HCMV)/HSV-1 scaffolding protein was shown to form oligomers, ranging from dimers to complexes containing 20 to 30 or more copies of the hybrid protein (19).
The regions of the HSV-1 and HCMV scaffolding proteins required for intermolecular self-association have been investigated, and different results have been obtained for each protein (4, 23, 36). In the HCMV scaffolding protein, an N-terminal domain located between residues 34 and 52 and containing amino acid residues highly conserved among alpha-, beta-, and gammaherpesviruses was found to be required for intermolecular interaction of the protein in the yeast-two hybrid system (36). A mutant protein with a single point mutation in this region failed to interact with the wild-type (wt) virus scaffolding protein, suggesting that this region is essential for self-interaction. In contrast, a study with the HSV-1 scaffolding protein using yeast two-hybrid and far-Western blot analyses implicated several regions in self-association (23). These included a predicted
-helical domain lying in the center of the protein between residues 164 and 219, a region within residues 54 to 164 on the N-terminal side of the central domain, and another on the C-terminal side. Disruption of the central domain did not abolish interaction of the mutant protein with the wt scaffolding protein in the yeast-two hybrid system, suggesting that there are multiple domains involved in intermolecular self-interaction. The region corresponding to the HCMV scaffolding protein N-terminal domain was not required for self-association in the yeast-two hybrid analysis. A weak interaction with the wt protein, however, was detected using a mutant containing amino acid residues 1 to 120 of the HSV-1 scaffolding protein as a probe in far-Western blot analyses, whereas a strong interaction was obtained using a mutant protein spanning the central core region only (amino acid residues 164 to 219).
We have investigated regions of the HSV-1 scaffolding protein implicated in intermolecular self-interaction by using the intact protein not linked to any other protein or domain, unlike the approaches used in previous studies. In particular, we have explored whether the region in the HSV-1 protein, homologous to the N-terminal region in HCMV, is important in this association. We have also determined whether disruption of any of these domains has any effect on capsid assembly and scaffold formation, an aspect that has not been studied previously.
|
|
|---|
Plasmids. With the exception of the triple mutation in domain 3, missense mutations were introduced into conserved domain 1, 2, 3, or 4 of the UL26.5 gene within the plasmid pGX262 DNA by ligation of a short restriction endonuclease fragment containing the mutation to the appropriate restriction endonuclease fragments (Fig. 1) (24). Two overlapping complementary synthetic oligonucleotides were annealed together to produce the mutant fragment. Mutant forms of the UL26.5 gene with defects in domain 1 were generated by ligating the BamHI-KpnI fragment, containing all the vector sequences from pGX262, to a BsmI-KpnI fragment encoding the carboxy-terminal portion of the UL26.5 open reading frame and a BamHI-BsmI synthetic double-stranded oligonucleotide containing mutations in domain 1. The mutant UL26.5 gene was identified by the presence of a novel NheI site that did not affect the wt virus UL26.5 amino acid sequence. The UL26.5 gene containing mutations in domain 2 was constructed by cleaving pGX262 with EagI and PpuMI and ligating the larger fragment to an EagI-PpuMI double-stranded oligonucleotide containing the missense mutations and a silent mutation, creating an NarI site. The mutation, E148A, was introduced into domain 3 by ligating a SmaI-SalI double-stranded oligonucleotide to the pGX262 PpuMI-KpnI fragment containing all the vector sequences, the PpuMI-SmaI UL26.5 gene fragment, and the SalI-KpnI UL26.5 gene fragment. The presence of the mutation was confirmed by sequence analysis. A PCR product containing a triple mutation, P146A, G147A, and E148A, in domain 3 was made using a forward primer with an EagI site and a reverse primer containing the mutations and an AscI site. The PCR product was cloned into the vector pCR2.1 TOPO (Invitrogen), and the cloned DNA was sequenced. A gene containing a triple mutation in domain 3 was constructed by ligating the EagI-AscI fragment containing the domain 3 mutations from pCR2.1 TOPO into the larger EagI-AscI fragment of pGX262. A triple mutation, L182A, L186A, and M189A, was engineered into domain 4 by ligating an AatII-Bsu36I oligonucleotide containing the mutations to the larger PpuMI-Bsu36I fragment from pGX262 and the PpuMI-AatI fragment from pGX262, spanning domain 3 and part of domain 4. A mutant gene with lesions in both domains 2 and 4 was constructed by ligating the smaller XhoI fragment from the plasmid containing the domain 2 mutant gene to the larger XhoI fragment from the plasmid containing the domain 4 mutations. The gene with defects in domains 1, 2, and 4 was obtained by ligating the larger BsmI-KpnI fragment from the plasmid carrying the domain 1 mutant gene to the smaller BsmI-KpnI fragment from the plasmid containing the gene with mutations in domains 2 and 4. Mutant genes were transferred as BglII fragments into the BglII site of the mammalian expression vector CMV10Bgl (22) and the baculovirus transfer vector pAcCL29.1B (24).
![]() View larger version (16K): [in a new window] |
FIG. 1. Mutations constructed for analysis of HSV-1 scaffolding protein. At the top, the locations of domains within the HSV-1 scaffolding protein that are conserved in seven alphaherpesviruses and the restriction endonuclease sites used in the construction of missense mutations are shown. The alphaherpesviruses used in the alignment were HSV-1, HSV-2, VZV, equine herpesvirus type 1, equine herpesvirus type 4, pseudorabies virus, and bovine herpesvirus type 1 proteins. Below, the amino acid sequence and location of domains 1 to 4 is shown, with residues that are conserved in all seven viruses displayed on the line below (26). The amino acid changes in the domains used in this study are listed to the right.
|
Confocal immunofluorescence microscopy. Linbro wells containing sterile glass coverslips were seeded with 7 x 104 Vero cells per well and transfected the following day with plasmid DNA using lipfectamine and Plus reagent (Life Technologies). Plus reagent (4 µl) was added to a tube containing 21 µl of plasmid DNA (0.5 to 1 µg) diluted in opti-mem (Life Technologies), and the sample was incubated for 15 min at room temperature. Diluted Lipofectamine (1 µl of Lipofectamine added to 24 µl of opti-mem) was mixed with the DNA solution treated with Plus reagent, and the sample was incubated at room temperature for 15 min. Prior to transfection, cells were washed twice with Dulbeccos medium lacking supplements and serum and overlaid with 200 µl of the same medium. After the transfection mixture was added to the cells, the sample was incubated at 37°C for 3 h. Complete Dulbeccos medium supplemented with 10% (vol/vol) fetal calf serum (1 ml) was added to the sample, and incubation continued at 37°C. The next day, cells were fixed in 5% (vol/vol) formaldehyde in phosphate-buffered saline (PBS) containing 2% (wt/vol) sucrose, permeabilized with 0.5% (vol/vol) Nonidet P-40 in PBS containing 10% (wt/vol) sucrose, and incubated at room temperature with diluted primary antibody for 2 h. After extensive washing with PBS containing 1% (vol/vol) calf serum, cells were incubated with FITC-GAM IgG, cy5-GAM IgG, or both secondary antibodies for 1 h at room temperature. Cells were washed in PBS containing 1% calf serum, mounted, and examined under a Zeiss LSM 510 confocal microscope, using a 63x oil immersion objective lens (NA 1.4) and lasers with excitation lines at 488 and 633 nm.
Electron microscopy. Immunoelectron microscopic studies were carried out as described by Preston et al. (26). Thin sections of baculovirus-infected cells embedded in Epon 812 resin were prepared as outlined by Addison et al. (1).
Purification of capsids. Sf21 cells (3 x 108) were infected with AcUL26.5 or a recombinant baculovirus expressing UL26.5 domain 2+4 mutant scaffolding protein, together with AcUL18/19/38 and AcUL35 at a multiplicity of infection of 5 PFU per cell for each virus. At 64 h postinfection, the cells were harvested and capsids were analyzed essentially as described previously (13) except that the samples were centrifuged on a 10 to 40% (wt/wt) sucrose gradient at 40,000 rpm for 20 min in a TST41 Sorvall rotor. Successive fractions were collected using a BioComp fractionator, and the proteins were analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). The separated proteins were stained with ammoniacal silver essentially as described by Harlow and Lane (10).
Analysis of scaffold-like particles. Sf21 cells (108) were infected with a multiplicity of infection of 5 PFU per cell of recombinant baculovirus expressing wt or mutant HSV-1 scaffolding protein. At 72 h postinfection, the cells were harvested, washed with PBS, frozen, and thawed five times in the presence of 300 µl of PBS. After the extract had been clarified by centrifugation for 5 min at 13,000 rpm, the sample was layered onto a 10 to 40% (wt/vol) sucrose gradient and the material was centrifuged for 1 h at 40,000 rpm in a TST41 Sorvall rotor. Fractions were collected using a BioComp fractionator, and the samples were analyzed by Western blotting or dialyzed against PBS to remove the sucrose. The material was screened for the presence of scaffold-like particles by treating the dialyzed samples with phosphotungstic acid and examining the material absorbed on to parlodion-covered grids under the electron microscope.
Detection of scaffolding proteins by Western blotting. Proteins were separated by SDS-PAGE, the separated proteins were blotted onto nitrocellulose paper, and Western blot analysis was carried out using the ECL system, a luminol-based detection method (Amersham Pharmacia Biotech).
|
|
|---|
-helices with a coiled-coil structure (23). In each domain, three hydrophobic residues were replaced with alanine residues with the aim of destabilizing coiled-coil interactions. The mutations engineered into domain 4 were identical to those made by Pelletier et al. (23). Initially, three amino acid changes were also introduced into the domain 1, including L31A. This leucine is conserved in the HCMV scaffolding protein and was shown by Wood et al. (36) to be required for intermolecular association of the HCMV scaffolding protein with itself. Subsequently, the corresponding single amino acid changes were made individually in domain 1. Three mutations were also made in domain 3 which, like domain 1, is conserved in beta- and gammaherpesviruses as well as alphaherpesviruses. In addition to the construction of mutant genes encoding proteins with lesions in each of the four conserved domains, genes specifying proteins with mutations in more than one conserved domain were produced. A construct containing triple mutations in both domains 2 and 4 was made and another mutant was produced with triple mutations in domains 1, 2, and 4. Details of the mutations made in the domains, together with restriction enzyme sites used in their construction, are shown in Fig. 1. Interaction of HSV-1 wt scaffolding protein with VZV homologue. Previous work, in which the HSV-1 and VZV scaffolding proteins were expressed transiently in mammalian cells and detected using an immunofluorescence assay, showed that the VZV scaffolding protein had a different pattern of distribution in the nucleus from that of the HSV-1 protein (13, 26) (Fig. 2a and b). The VZV scaffolding protein was present in localized regions, probably containing large aggregates of the protein, whereas the HSV-1 counterpart was usually dispersed throughout the nucleus and had a granular appearance. This observation was exploited to develop an assay for scaffolding protein interaction. Vero cells were cotransfected with plasmids containing the HSV-1 and VZV genes under the control of the HCMV major immediate-early promoter, and the expressed proteins were detected by indirect immunofluorescence. In cells containing both proteins, the pattern of distribution of the VZV scaffolding protein generally resembled that of the HSV-1 protein when expressed on its own (Fig. 2a and c to e). Occasionally, the VZV protein gave a spotty fluorescence pattern, and in such cases the HSV-1 scaffolding protein always colocalized with the VZV protein, suggesting that the two proteins interacted with each other (Fig. 2f to h). To confirm that the VZV scaffolding protein was associated with the HSV-1 protein, insect cells were coinfected with recombinant baculoviruses expressing the two scaffolding proteins and analyzed by immunoelectron microscopy. Thin sections of baculovirus-infected cells embedded in acrylic resin were incubated with mouse monoclonal antibody 5010, which is specific for the HSV-1 scaffolding protein, and a rabbit antiserum, which is specific for the VZV homologue. The sections were subsequently treated with GAM IgG coupled to 10-nm colloidal gold and GAR IgG coupled to 30-nm colloidal gold. As a control, mouse monoclonal antibodies specific for an unrelated HSV-1 protein (VP16) and preimmune rabbit serum were used in place of the primary antibodies. Both 10- and 30-nm gold particles were concentrated over aggregates of scaffolding protein in samples treated with antibodies specific for HSV-1 and VZV scaffolding proteins but not in preparations incubated with control antibodies. This result suggested that the HSV-1 and VZV scaffolding proteins were both present in the aggregates (Fig. 3a and b). Instead of being concentrated in regions containing scaffold-like particles, the HSV-1 antibodies were mainly found clustered over areas containing tubular structures, which were uncommon in insect cells expressing the HSV-1 protein on its own but frequently observed in cells expressing the VZV scaffolding protein on its own. It is therefore likely that the VZV scaffolding protein can influence the structure that the HSV-1 protein adopts. To confirm that the HSV-1 and VZV specific antibodies did not cross-react with the VZV and HSV-1 scaffolding proteins, respectively, thin sections of insect cells containing only the VZV or HSV-1 protein were treated with both primary antibodies and subsequently both secondary antibodies. No cross-reaction was observed between the HSV-1 specific monoclonal antibody and VZV scaffolding protein and, similarly, between the VZV rabbit antibody and HSV-1 protein in the immunoelectron microscopic analysis (Fig. 3c and d) and in the immunofluorescence assay used to detect the VZV and HSV-1 scaffolding proteins (data not shown). In addition, no cross-reaction was observed between the GAM IgG and the rabbit polyclonal antibody and with GAR IgG and the mouse monoclonal antibody.
![]() View larger version (39K): [in a new window] |
FIG. 2. Colocalization of VZV and HSV-1 scaffolding proteins. Digital confocal images of transfected Vero cells expressing the VZV scaffolding protein (a), the HSV-1 wt scaffolding protein (b), or VZV and HSV-1 proteins (c to h). Bound rabbit polyclonal antibodies (specific for the VZV protein) were visualized with Cy5-GAR IgG (red), and mouse monoclonal antibodies (specific for the HSV-1 protein) were detected with FITC-GAM IgG (green). In both sets of three images for cells dually expressing the VZV and HSV proteins, the image in the right panel represents the merged images in the left and middle panels. Bar, 10 µm.
|
![]() View larger version (159K): [in a new window] |
FIG. 3. Identification of aggregates of HSV-1 and VZV scaffolding proteins by immunoelectron microscopy. Thin sections of sf21 cells infected with baculoviruses expressing VZV and HSV-1 scaffolding proteins (a and b) and cells singly infected with baculovirus expressing the VZV scaffolding protein (c) or the HSV-1 scaffolding protein (d) were prepared. The samples were incubated with rabbit antiserum specific for VZV scaffolding protein and mouse monoclonal antibody specific for the HSV-1 homologue (a, c, and d) or control antibodies (b) and subsequently treated with GAM IgG conjugated to 10-nm gold particles and GAR IgG conjugated to 30-nm gold particles. Bar, 0.5 µm; large arrow, 30-nm gold particle; small arrow, 10-nm gold particle.
|
![]() View larger version (41K): [in a new window] |
FIG. 4. Interaction of HSV-1 mutant scaffolding proteins with VZV homologue. Vero cells were transfected with a plasmid expressing a mutant HSV-1 scaffolding protein together with a construct containing the homologous VZV gene, and the proteins were detected using an indirect immunofluorescence assay. Digital confocal images in groups of three represent cells containing the VZV scaffolding protein plus domain 1 triple mutant protein (a, b, c), domain 2 mutant (d, e, f), domain 3 mutant (g, h, i), domain 4 mutant (j, k, l), and domain 2+4 mutant (m, n, o). Bound mouse antibodies (specific for the HSV-1 protein) were visualized with FITC-GAM IgG (green), and bound rabbit antibodies (specific for the VZV protein) were detected with Cy5-GAR IgG (red). In each set, the image in the right panel represents the merged images in the left and middle panels. Bar, 10 µm.
|
![]() View larger version (59K): [in a new window] |
FIG. 5. Interaction of domain 1 mutants containing single amino acid changes with VZV scaffolding protein. Digital confocal images in groups of three represent transfected Vero cells dually expressing the VZV scaffolding protein and domain 1 mutants Y28A (a, b, c), Q30A (d, e, f), or L31A (g, h, i). Bound mouse monoclonal antibodies (specific for the HSV-1 protein) were visualized with FITC-GAM IgG, and bound rabbit polyclonal antibodies (specific for the VZV protein) were identified using Cy5-GAR IgG. In each set, the image in the right panel represents the merged images in the left and middle panels. Bar, 10 µm.
|
![]() View larger version (146K): [in a new window] |
FIG. 6. Participation of mutant scaffolding proteins in capsid assembly. Insect cells were infected with a recombinant baculovirus expressing wt or mutant scaffolding protein together with a virus expressing VP5, VP19C, and VP23. Samples were harvested at 50 h postinfection, fixed, and embedded, and thin sections were examined for the presence of capsids under the electron microscope. Shown are electron micrographs of a portion of a cell expressing VP5, VP19C, VP23, and HSV-1 wt scaffolding protein (a), domain 1 mutant protein (b), domain 2 mutant protein (c), domain 3 mutant protein (d), domain 4 mutant protein (e), or domain 2+4 mutant protein (f). Arrows, incomplete capsids; bar, 0.5 µm.
|
![]() View larger version (74K): [in a new window] |
FIG. 7. Sucrose gradient sedimentation analysis of extracts from insect cells infected with recombinant baculoviruses expressing HSV-1 capsid shell proteins and either wt scaffolding protein (a and c) or mutant 2+4 scaffolding protein (b and d). The extracts were sedimented through 10 to 40% sucrose gradients, and successive fractions were collected. The proteins in each fractions were analyzed by SDS-PAGE and detected by silver staining (a and b), and the scaffolding protein in each fraction was detected by Western blotting using the monoclonal antibody 406 (c and d). The short arrow indicates the major baculovirus capsid protein p39 and the long arrow shows the direction of sedimentation. The positions of the HSV-1 capsid proteins are indicated on the left and in the peak fraction in the wt virus sample. On the right, the positions of the Mr standards are given.
|
![]() View larger version (109K): [in a new window] |
FIG. 8. Effect of proteolytic cleavage of mutant scaffolds within capsids. Insect cells were multiply infected with a recombinant baculovirus expressing VP5, VP19C, and VP23, a virus expressing the protease, and a virus expressing wt or mutant scaffolding protein. Shown are electron micrographs of a thin section of a cell expressing VP5, VP19C, and VP23, the UL26 gene product, and wt scaffolding protein (a) or domain 1 (b), domain 2 (c), domain 3 (d), or domain 4 (e) mutant scaffolding protein. The arrows point to capsids containing distinctive scaffolds. Bar, 0.5 µm.
|
![]() View larger version (61K): [in a new window] |
FIG. 9. Aggregates of wt and mutant scaffolding proteins. Insect cells were infected with a single recombinant baculovirus expressing the wt protein or a mutant scaffolding protein and harvested at 72 h postinfection. Extracts were prepared, and the clarified extracts were layered onto 10 to 40% sucrose gradients and centrifuged. Fractions were collected, starting from the top of the gradient. (a) The proteins from each gradient were separated on an SDS-10% polyacrylamide gel, and the scaffolding protein was detected by Western blotting, using monoclonal antibody to the UL26.5 protein. The arrow indicates the direction of sedimentation. (b) The material from selected fractions from each gradient was negatively stained and examined under the electron microscope. Scaffold-like particles were observed in the peak fraction (fraction 7) from gradients of wt protein and domain 3 mutant scaffolding protein only. Bar, 100 nm.
|
![]() View larger version (44K): [in a new window] |
FIG. 10. Interaction of VP5 with mutant scaffolding proteins. Vero cells were cotransfected with a plasmid expressing VP5 and another expressing the wt protein or a mutant HSV-1 scaffolding protein. Transfections with individual plasmids were also carried out. Proteins were detected using an indirect immunofluorescence assay. The top six digital confocal images represent cells expressing VP5 (a), wt scaffolding protein (b), VP22a (c), domain 1 mutant containing three mutations (d), domain 2+4 mutant (e), and domain 1+2+4 mutant (f). The subsequent confocal images, in series of three, represent cells containing wt scaffolding protein (preVP22a) and VP5 (g, h, i), VP22a and VP5 (j, k, l), domain 1 triple mutant and VP5 (m, n, o), domain 2 + 4 and VP5 (p, q, r), and domain 1+2+4 and VP5 (s, t, u). Bound mouse monoclonal antibodies (specific for the HSV-1 protein) were visualized with FITC-GAM IgG, and bound rabbit polyclonal antibodies (specific for VP5) were identified using Cy5-GAR IgG. In each set of three images of dually expressed HSV proteins, the image in the right panel represents the merged images present in the left and middle panels. Bar, 10 µm.
|
|
|
|---|
|
View this table: [in a new window] |
TABLE 1. Characterization of HSV-1 mutant scaffolding proteins
|
The findings from the yeast two-hybrid study on self-interaction of the HSV-1 scaffolding protein suggested that there were several sites involved in self-association, and our results are consistent with this idea since none of the mutations in the individual domains abolished self-interaction of the protein (23). Recently, further evidence in favor of multiple interactions within the scaffold itself has been obtained from a study of the structure of HSV-1 procapsids by using cryoelectron microscopy. Radial density profiles from three-dimensional density maps revealed three peaks of density in the region corresponding to the scaffolding protein, which was interpreted to represent regions of condensed scaffolding protein domains separated by flexible linkers (21).
Various programs for predicting protein secondary structures, such as Chou-Fasman (3) and Garnier-Robson (9), suggest that several of the conserved regions within the scaffolding protein have a high propensity for
-helicity, notably domains 2 and 4. Pelletier et al. (23) speculated that these two regions formed short coiled coils and that the scaffolding protein associated with itself via multiple weak homomeric coiled-coil interactions. In our study, the amino acid residues mutated within domain 2 or 4 were selected on that basis. However, more recent algorithms, for example, Psipred (12), do not predict any
-helices in these regions and suggest that there is a much higher number of ß-sheets than previously predicted. These models have to be tested experimentally to determine the underlying structural mechanism of interaction. Whether or not domains 2 or 4 form coiled coils, the mutations introduced in these regions clearly had an effect on scaffold formation.
Previous work with the HCMV and HSV-1 scaffolding proteins in the yeast two-hybrid system suggested that intermolecular self-interaction of these proteins was important for association with the major capsid protein, VP5, particularly when deletion scaffolding protein mutants were assayed (23, 36). By contrast, in our study, domain 1 and 2+4 mutant proteins, both of which had a reduced ability to self-interact, were not significantly impaired in their interaction with VP5 in a transient-expression assay. Subsequent analysis of the domain 2, 3, and 4 mutants showed that these proteins were also able to associate with VP5 and alter its intracellular distribution (data not shown). Only the domain 1+2+4 mutant had a reduced capacity to localize VP5 to the nucleus, and this was probably because the mutant protein itself was transported inefficiently to the nucleus. Our results suggest that the formation of large complexes of the scaffolding protein is not required for the interaction of the scaffolding protein with VP5. These findings are consistent with previous work showing that purified VP5 preferentially formed complexes with low-molecular-weight aggregates of the purified scaffolding protein than with large oligomers (19). Our data are in keeping with a model in which the scaffolding protein interacts with VP5, forming a small complex which is transported into the nucleus where it associates with the triplexes, assembling into the procapsid by the subsequent addition of further VP5-scaffolding protein complexes and triplexes (19, 32). The ability of VP5 to interact with domain 1, 2, and 4 mutant scaffolding proteins, despite their reduced capacities to self-associate, explains why these mutants still functioned in capsid assembly. The scaffolding protein-VP5 interaction would lead to an increased localized concentration of the scaffolding protein in the presence of the triplexes, favoring self-association of the scaffolding protein, which would promote the formation of the procapsid.
|
|
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»